Table 3.
Risk of MACEs by therapeutic class in the Cox and Fine–Gray models
| IPTW Cox |
IPTW Fine–Gray |
|||||
|---|---|---|---|---|---|---|
| HRw | 95% CI | P-value | SHRw | 95% CI | P-value | |
| Treatments (ref: TNF inhibitors) | – | – | <10−4 | – | – | <10−4 |
| IL-12/23 inhibitor | 2.0 | 1.3, 3.0 | <10−4 | 2.1 | 1.5, 2.9 | <10−3 |
| IL-17 inhibitors | 1.9 | 1.2, 3.0 | <10−3 | 2.3 | 1.5, 3.0 | <10−3 |
| Apremilast | 1.3 | 0.8, 2.2 | 0.31 | 1.4 | 0.8, 2.4 | 0.12 |
MACE: major adverse cardiovascular event; HRw: weighted hazard ratio; SHRw: weighted subhazard ratio; IPTW: inverse probability of treatment weighting.